CNSJF yields 1234.57% · PFE yields 6.13%● Live data
📍 CNSJF pulled ahead of the other in Year 1
Combined, CNSJF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CNSJF + PFE for your $10,000?
China Sanjiang Fine Chemicals Company Limited, an investment holding company, manufactures and supplies ethylene oxide and glycol, propylene, polypropylene, methyl tert-butyl ether (MTBE), and surfactants in the People's Republic of China. Its ethylene oxide is used as an intermediary component for the production of ethylene derivative products that include ethanolamines and glycol ethers, and a range of surfactants; ethylene glycol is used to produce other bio-organic chemical products that comprise mono ethylene glycol; propylene is used in the production of polypropylene, acrylonitrile, propylene oxide, acetone, etc.; polypropylene is a thermoplastic resin used in knitting, injection molding, film, fiber, and pipe products; MTBE, a gasoline additive used as an oxygenate to raise the octane number and used as a fuel component in fuel for gasoline engines; and surfactants are applied in various industries as scouring agents, moisturizing agents, emulsifiers, and solubilisers. The company also produces and supplies other chemical products, such as carbon four; crude pentene; and industrial gases, such as oxygen, nitrogen, and argon. In addition, it offers processing services for polypropylene, MTBE, and surfactants; and lease and storage services, as well as provides asset management and supply chain management services. Further, the company is involved in the construction and management of a pipe network at Jiaxing Port Chemical Industrial Park; manufacture and sale of fertilisers, plastics, alcohol ethoxylate, nonylphenols, textile auxiliaries, and polyethylene; and equipment rental. China Sanjiang Fine Chemicals Company Limited was incorporated in 2009 and is headquartered in Jiaxing, the People's Republic of China.
Full CNSJF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.